Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management

Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma.

(2017) K. T. Flaherty et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors.

(2017) R. Kefford et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes.

(2017) F. E. Meier et al.   JOURNAL OF CLINICAL ONCOLOGY

Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy.

(2017) M. E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

(2017) A. Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).

(2017) J. R. Infante et al.   JOURNAL OF CLINICAL ONCOLOGY

RASMutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

(2012) Fei Su et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erratum: Ras and Raf pathways in epidermis development and carcinogenesis

(2011) F Kern et al.   BRITISH JOURNAL OF CANCER

RAF inhibition and induction of cutaneous squamous cell carcinoma

(2011) Caroline Robert et al.   CURRENT OPINION IN ONCOLOGY

Kutane Nebenwirkungen der medikamentösen Tumortherapie

(2011) A. Degen et al.   HAUTARZT

RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors

(2011) Patrick A. Oberholzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Disseminated follicular eruption during therapy with the MEK inhibitor AZD6244

(2011) Christiane Querfeld et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours

(2010) Ingrid M. E. Desar et al.   ACTA ONCOLOGICA

Targeting BRAF for patients with melanoma

(2010) H-T Arkenau et al.   BRITISH JOURNAL OF CANCER

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

(2010) U. Banerji et al.   CLINICAL CANCER RESEARCH

Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib

(2010) Emma Guttman-Yassky et al.   EUROPEAN JOURNAL OF CANCER

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

(2010) Yevgeniy Balagula et al.   INVESTIGATIONAL NEW DRUGS

Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician

(2010) Ralf Gutzmer et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer

(2010) Mario E. Lacouture et al.   JOURNAL OF CLINICAL ONCOLOGY

Opposing roles for calcineurin and ATF3 in squamous skin cancer

(2010) Xunwei Wu et al.   NATURE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of the Cutaneous Side Effects of Therapeutic Epidermal Growth Factor Receptor Inhibition

(2010) Martin Reck et al.   ONKOLOGIE

Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies

(2009) Diamant Thaçi et al.   CLINICS IN DERMATOLOGY

MANAGEMENT OF SKIN RASH DURING EGFR-TARGETED MONOCLONAL ANTIBODY TREATMENT FOR GASTRO INTESTINAL MALIGNANCIES: CANADIAN RECOMMENDATIONS

(2009) Barb Melosky et al.   Current Oncology

Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

(2009) Jean Philippe Arnault et al.   JOURNAL OF CLINICAL ONCOLOGY

VDR and MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by lithocholic acid

(2009) Mark Peric et al.   MOLECULAR IMMUNOLOGY

Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes

(2008) Aminah Jatoi et al.   CANCER

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Ras oncogenes: split personalities

(2008) Antoine E. Karnoub et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics

(2007) Lisa A. Hammond-Thelin   DERMATOLOGIC CLINICS